USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Generics specialist Mylan has moved to block a hostile takeover bid by Israeli company Teva by setting up an independent Dutch foundation which has exercised its call option to acquire preferred shares in Mylan. 24 July 2015
Swedish pharma company Karolinska Development is divesting its entire shareholding in Pharmanest to a consortium consisting of The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Recipharm Venture Fund and Praktikerinvest. 9 July 2015
Celladon has issued a business update detailing its intention to suspend further development of its experimental gene therapy Mydicar and other clinical programs. 28 June 2015
Swiss drug major Novartis has highlighted its strong innovation momentum and said it expects to increase core margin in 2015 due to portfolio transformation. 18 June 2015
Iclaprim, a new antibiotic from Motif Bio, could fill a major market void and achieve over $1 billion in sales per year, according to analysts at Northland Capital Partners. 27 May 2015
Skyepharma’s underlying business is strong now the company has repaid bonds and other costly loans, according to a new report from Edison Investment Research. 18 May 2015
Privately-held Moderna Therapeutics, a specialist in messenger RNA, has launched Elpidera LLC, a new venture focused solely on the advancement of mRNA-based medicines for rare diseases. 12 May 2015
Spanish pharma company Zeltia is laying the groundwork for a period of significant potential growth and value creation, according to a report from investment research company Edison, which has raised its valuation. 18 March 2015
UK pharma major GlaxoSmithKline says that it plans to dispose of half its current 12.4% stake in South African drugmaker Aspen Pharmacare. 13 March 2015
The Bill & Melinda Gates Foundation has committed to invest $52 million in private biopharma company CureVac, the biggest equity investment the Foundation has ever made in a biotech company. 6 March 2015
Three former pharma and health care executives have formed a new partnership to provide strategic support to pharma companies in identifying and leveraging revenue opportunities. 18 February 2015
Nutrinia, a developer of oral insulin therapies to treat rare gastrointestinal disorders in babies, has successfully completed a $12 million round of funding. 18 December 2014
Belgian drugmaker UCB and private equity firms Avista Capital and Advent International have mutually agreed to terminate an agreement whereby UCB would have divested its specialty generics unit Kremers Urban Pharmaceuticals to the private equity firms for $1.5 billion. 17 December 2014
UK-based antibody therapeutics specialist Crescendo Biologics has received another equity investment from Astellas Venture Management to support the discovery and development of new Humabody antibody fragment therapeutics in oncology. 16 December 2014
Following AbbVie’s recent abandonment of a $53 billion takeover offer, Ireland-headquartered drugmaker Shire (LSE: SHP) has announced it is to relocate more than 500 positions from Chesterbrook, Pennsylvania to Massachusetts. 19 November 2014
The chief executive of the capital management company assisting Valeant Pharmaceuticals in its attempts to purchase Allergan urged it to initiate an open sale process as reports emerged that the company had entered negotiations with Actavis. 10 November 2014
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news